vs

Side-by-side financial comparison of HireQuest, Inc. (HQI) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $7.0M, roughly 1.8× HireQuest, Inc.). HireQuest, Inc. runs the higher net margin — 22.8% vs -1398.3%, a 1421.1% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -13.0%). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -8.6%).

Quest, also known as Quest - Hire a Hero, is a Singapore-based technology company founded in 2021 that operates an AI-powered on-demand services marketplace. The platform connects users with verified workers, known as “Heroes” to complete a wide range of tasks.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

HQI vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.8× larger
RNA
$12.5M
$7.0M
HQI
Growing faster (revenue YoY)
RNA
RNA
+447.0% gap
RNA
434.0%
-13.0%
HQI
Higher net margin
HQI
HQI
1421.1% more per $
HQI
22.8%
-1398.3%
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-8.6%
HQI

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
HQI
HQI
RNA
RNA
Revenue
$7.0M
$12.5M
Net Profit
$1.6M
$-174.4M
Gross Margin
Operating Margin
18.6%
-1513.5%
Net Margin
22.8%
-1398.3%
Revenue YoY
-13.0%
434.0%
Net Profit YoY
-27.8%
-117.0%
EPS (diluted)
$0.11
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HQI
HQI
RNA
RNA
Q4 25
$7.0M
Q3 25
$8.5M
$12.5M
Q2 25
$7.6M
$3.8M
Q1 25
$7.5M
$1.6M
Q4 24
$8.1M
$3.0M
Q3 24
$9.4M
$2.3M
Q2 24
$8.7M
$2.0M
Q1 24
$8.4M
$3.5M
Net Profit
HQI
HQI
RNA
RNA
Q4 25
$1.6M
Q3 25
$2.3M
$-174.4M
Q2 25
$1.1M
$-157.3M
Q1 25
$1.4M
$-115.8M
Q4 24
$2.2M
$-102.3M
Q3 24
$-2.2M
$-80.4M
Q2 24
$2.0M
$-70.8M
Q1 24
$1.6M
$-68.9M
Operating Margin
HQI
HQI
RNA
RNA
Q4 25
18.6%
Q3 25
28.8%
-1513.5%
Q2 25
13.7%
-4448.7%
Q1 25
19.8%
-8360.9%
Q4 24
28.0%
-4069.6%
Q3 24
-28.6%
-4200.9%
Q2 24
31.0%
-4040.4%
Q1 24
25.0%
-2178.6%
Net Margin
HQI
HQI
RNA
RNA
Q4 25
22.8%
Q3 25
27.1%
-1398.3%
Q2 25
13.9%
-4089.3%
Q1 25
18.2%
-7360.0%
Q4 24
27.5%
-3439.5%
Q3 24
-23.4%
-3441.7%
Q2 24
23.5%
-3461.8%
Q1 24
19.2%
-1943.4%
EPS (diluted)
HQI
HQI
RNA
RNA
Q4 25
$0.11
Q3 25
$0.16
$-1.27
Q2 25
$0.08
$-1.21
Q1 25
$0.10
$-0.90
Q4 24
$0.15
$-0.80
Q3 24
$-0.16
$-0.65
Q2 24
$0.15
$-0.65
Q1 24
$0.12
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HQI
HQI
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$68.3M
$1.9B
Total Assets
$88.2M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HQI
HQI
RNA
RNA
Q4 25
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$575.8M
Q1 24
$471.4M
Stockholders' Equity
HQI
HQI
RNA
RNA
Q4 25
$68.3M
Q3 25
$67.8M
$1.9B
Q2 25
$66.0M
$1.2B
Q1 25
$65.6M
$1.3B
Q4 24
$64.8M
$1.4B
Q3 24
$62.9M
$1.5B
Q2 24
$65.4M
$1.2B
Q1 24
$63.9M
$830.9M
Total Assets
HQI
HQI
RNA
RNA
Q4 25
$88.2M
Q3 25
$94.9M
$2.1B
Q2 25
$94.3M
$1.4B
Q1 25
$93.7M
$1.5B
Q4 24
$94.0M
$1.6B
Q3 24
$102.7M
$1.6B
Q2 24
$107.6M
$1.3B
Q1 24
$105.9M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HQI
HQI
RNA
RNA
Operating Cash FlowLast quarter
$6.6M
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
4.12×
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HQI
HQI
RNA
RNA
Q4 25
$6.6M
Q3 25
$1.0M
$-156.2M
Q2 25
$2.6M
$-199.7M
Q1 25
$1.9M
$-124.8M
Q4 24
$8.7M
$-99.9M
Q3 24
$4.2M
$-65.6M
Q2 24
$188.0K
$-65.0M
Q1 24
$-967.0K
$-70.4M
Free Cash Flow
HQI
HQI
RNA
RNA
Q4 25
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
FCF Margin
HQI
HQI
RNA
RNA
Q4 25
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Capex Intensity
HQI
HQI
RNA
RNA
Q4 25
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Cash Conversion
HQI
HQI
RNA
RNA
Q4 25
4.12×
Q3 25
0.45×
Q2 25
2.41×
Q1 25
1.36×
Q4 24
3.90×
Q3 24
Q2 24
0.09×
Q1 24
-0.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons